1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Market Spotlight: Sarcoma, Pharma Intelligence

Market Spotlight: Sarcoma, Pharma Intelligence

  • September 2019
  • 54 pages
  • ID: 5779998
  • Format: PDF
  • By Pharma Intelligence


Table of Contents

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026.
Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).
The approved drugs in the sarcoma space focus on a wide variety of targets. The majority of approved drugs are administered via the intravenous route, with two products being available in oral formulations.
The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II, with only one drug in the NDA/BLA stage.
Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular/subretinal/subconjunctival, intradermal, intramuscular, intraarterial, intratumoral, and topical formulations.
High-impact upcoming events in the sarcoma space comprise topline Phase II trial results for ADP-A2M4CD8 and an expected PDUFA date for tazemetostat.
The overall likelihood of approval of a Phase I sarcoma asset is 11.1%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been 16 licensing and asset acquisition deals involving sarcoma drugs during 2014–19. The largest deal during the period was the $1,150m strategic collaboration and licensing agreement signed in 2014 between Adaptimmune and GlaxoSmithKline to develop and commercialize Adaptimmune’s NY-ESO-1 program.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia.
Clinical trial activity in the sarcoma space is dominated by completed trials. Merck and Co has the highest number of completed clinical trials for sarcoma, with 19 trials.
Merck and Co leads industry sponsors with the highest overall number of clinical trials for sarcoma, followed by Novartis.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Recurrent Malignant Glioma - Pipeline Review, H2 2019

Recurrent Malignant Glioma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Recurrent Malignant Glioma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H2 2019, provides an overview of ...

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019’; Histone Lysine ...

Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H2 2019

Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H2 2019SummaryProto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC pipeline Target constitutes ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on